Clinical Trial Update: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating subcutaneous tildrakizumab for moderate-to-severe chronic plaque psoriasis with long-term extension; trial completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Tildrakizumab (tildrakizumab)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-06-27